- Home
- ARQT vs ALX Comparison
ARQT vs ALX Comparison
Compare ARQT & ALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ALX
- Stock Information
- Founded
- ARQT 2016
- ALX 1928
- Country
- ARQT United States
- ALX United States
- Employees
- ARQT N/A
- ALX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ALX Real Estate Investment Trusts
- Sector
- ARQT Health Care
- ALX Real Estate
- Exchange
- ARQT Nasdaq
- ALX Nasdaq
- Market Cap
- ARQT 1.1B
- ALX 1.1B
- IPO Year
- ARQT 2020
- ALX N/A
- Fundamental
- Price
- ARQT $13.28
- ALX $190.73
- Analyst Decision
- ARQT Strong Buy
- ALX Sell
- Analyst Count
- ARQT 5
- ALX 1
- Target Price
- ARQT $17.00
- ALX $125.00
- AVG Volume (30 Days)
- ARQT 1.9M
- ALX 11.1K
- Earning Date
- ARQT 02-25-2025
- ALX 02-10-2025
- Dividend Yield
- ARQT N/A
- ALX 9.40%
- EPS Growth
- ARQT N/A
- ALX N/A
- EPS
- ARQT N/A
- ALX 9.25
- Revenue
- ARQT $138,708,000.00
- ALX $233,399,000.00
- Revenue This Year
- ARQT $215.24
- ALX N/A
- Revenue Next Year
- ARQT $53.63
- ALX N/A
- P/E Ratio
- ARQT N/A
- ALX $20.50
- Revenue Growth
- ARQT 182.84
- ALX 8.52
- 52 Week Low
- ARQT $5.38
- ALX $184.76
- 52 Week High
- ARQT $16.20
- ALX $251.63
- Technical
- Relative Strength Index (RSI)
- ARQT 47.68
- ALX 41.72
- Support Level
- ARQT $12.09
- ALX $185.75
- Resistance Level
- ARQT $15.09
- ALX $192.90
- Average True Range (ATR)
- ARQT 0.83
- ALX 4.58
- MACD
- ARQT -0.13
- ALX 0.73
- Stochastic Oscillator
- ARQT 39.67
- ALX 36.90
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.